<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105815</url>
  </required_header>
  <id_info>
    <org_study_id>KY2021-567</org_study_id>
    <nct_id>NCT05105815</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>An Exploratory Study on the Safety and Effectiveness of Autoimmune Cell Therapy Sensitized With Liver Cancer Neoantigen in Patients With High Risk of Recurrence After Surgical Resection of Primary Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Immupeutics Medicine Technology Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are&#xD;
      going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune&#xD;
      cell injection&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>18 months</time_frame>
    <description>The time between the NeoAg/aeTSA CTL initiation and the onset of tumor recurrence or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>24 months</time_frame>
    <description>From the beginning of NeoAg/aeTSA CTL initiation to the time of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ30</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>IPM001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A neoantigen/tumor-specific antigen sensitized autoimmune cell injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPM001</intervention_name>
    <description>IPM001 will be used against tumor cells</description>
    <arm_group_label>IPM001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  understand and voluntarily sign a written informed consent;&#xD;
&#xD;
          -  Age: from 18 to 75 years, No restriction on gender;&#xD;
&#xD;
          -  Patients must have primary hepatocellular carcinoma;&#xD;
&#xD;
          -  Clinical stage: stage Ia~III a;&#xD;
&#xD;
          -  Child-pugh score ≤7;&#xD;
&#xD;
          -  HLA-A02 and consistent with ≥1 NeoAg or ≥2 aeTSA peptide bank;&#xD;
&#xD;
          -  ECOG PS score: 0~2;&#xD;
&#xD;
          -  Laboratory values as follow:&#xD;
&#xD;
          -  White blood cell count ≥ 3×109/L; Neutrophils: more than 1.5 × 109/L; Hemoglobin: more&#xD;
             than 85g/L; Platelets: more than 5 × 1010/L; Total bilirubin:≤2 × ULN; Serum AST(GOT)&#xD;
             and ALT(GPT)≤2.5 × ULN; Albumin ≥3.0 g/dL (30 g/L); Serum creatinine: less than 1.5 ×&#xD;
             ULN; Coagulation time was basically normal, PT extension ≤4s; No serious&#xD;
             cardiopulmonary disease;&#xD;
&#xD;
          -  Blood collection body weight: male &gt; 50 kg, female &gt; 45 kg;&#xD;
&#xD;
          -  No obvious hereditary diseases;&#xD;
&#xD;
          -  Expected survival: more than 6 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has known distant organ metastasis;&#xD;
&#xD;
          -  Suffer from lymphoma or leukemia or MDS (myelodysplastic syndrome), etc.;&#xD;
&#xD;
          -  Woman be pregnant or lactating;&#xD;
&#xD;
          -  Suffer from mental or neurological diseases that are resistant to control;&#xD;
&#xD;
          -  The investigator judges that it is not suitable to participate in this clinical&#xD;
             research (such as poor compliance, etc.);&#xD;
&#xD;
          -  Patients infected with human immunodeficiency virus (commonly known as AIDS) or&#xD;
             Treponema pallidum (commonly known as syphilis);&#xD;
&#xD;
          -  Patients with a history of other malignant tumors in the past 5 years;&#xD;
&#xD;
          -  Organ transplantation or Myelosuppression;&#xD;
&#xD;
          -  History of drug abuse or alcohol abuse;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hao Zhang, PhD</last_name>
    <phone>8613917775888</phone>
    <email>drhao@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan hospital Fudan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Hao Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

